Biotinylated Human HLA-G Tetramer Protein

产品信息(Product Info)

Recombinant Biotinylated Human HLA-G Tetramer Protein is expressed from Expi293 with His tag and Avi tag at the C-terminal,tetramer is assembled by biotinylated monomer and streptavidin. It contains Gly25-Thr305(HLA-G),Ile21-Met119(B2M) and RIIPRHLQL peptide.[Accession | P17693-1(HLA-G)&P61769(B2M)&RIIPRHLQL]

分子量大小(Molecular Weight)

The protein has a predicted MW of 258 kDa. Due to glycosylation, the protein migrates to 260-265 kDa under Non reducing (N) condition based on Tris-Bis PAGE result.


Less than 1EU per μg by the LAL method.


> 95% as determined by Tris-Bis PAGE
> 95% as determined by HPLC


Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 5% trehalose is added as protectant before lyophilization.


Centrifuge tubes before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.


-20 to -80°C for 12 months as supplied from date of receipt.
-20 to -80°C for 3-6 months in unopened state after reconstitution.
2-8°C for 2-7 days after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please avoid freeze-thaw cycles.

产品数据(Assay Data)
Tris-Bis PAGE

Biotinylated Human HLA-G Tetramer on Tris-Bis PAGE under Non reducing (N) condition. The purity is greater than 95%.


The purity of Biotinylated Human HLA-G Tetramer is greater than 95% as determined by SEC-HPLC.

Blocking Data

Serial dilutions of Anti-LILRB2 Antibody were added into Biotinylated HLA-G Complex Tetramer, His Tag: Human LILRB2, mFc Tag binding reactioins. The half maximal inhibitiory concentration (IC50) is 0.29μg/ml.

SPR Data

Human LILRB2, hFc Tag captured on CM5 Chip via Protein A can bind Biotinylated Human HLA-G Tetramer, His-Avi Tag with an affinity constant of 4.38 nM as determined in SPR assay (Biacore T200).


HLA-G is a molecule that was first known to confer protection to the fetus from destruction by the immune system of its mother, thus critically contributing to fetal-maternal tolerance. The first functional finding constituted the basis for HLA-G research and can be summarized as such: HLA-G, membrane-bound or soluble, strongly binds its inhibitory receptors on immune cells (NK, T, B, monocytes/dendritic cells), inhibits the functions of these effectors, and so induces immune inhibition.


HLA G antigen; sHLA-G; b2 microglobulin; HLA G; HLAG; HLA-G; MHC Class I Antigen G; MHC class Ib antigen; MHC-G; sHLA-G


(1) Krijgsman D, Roelands J, Hendrickx W, Bedognetti D, Kuppen PJK. HLA-G: A New Immune Checkpoint in Cancer? Int J Mol Sci. 2020 Jun 25;21(12):4528. doi: 10.3390/ijms21124528. PMID: 32630545; PMCID: PMC7350262.